相关实验视频
Updated: Jun 29, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.4K
在初步评估中,在没有药物停用或确认测试的情况下,对原发性阿尔多斯特隆症诊断的可行性
Jorge Gabriel Ruiz-Sánchez1,2, Álvaro Fernández Sánchez3, Diego Meneses3
1Endocrinology Department. Hospital Universitario Fundación Jiménez Díaz, 28040, Madrid, Spain. jorgeg.ruiz@quironsalud.es.
Endocrine
|April 3, 2024
概括
诊断原发性阿尔多斯特症 (PA) 是可行的,与阿尔多斯特与素的比率 (ARR),即使患者在素- ангиотензин-阿尔多斯特系统 (RAAS) 干扰药物. 一个ARR大于50结合低血强烈表明PA.
科学领域:
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
- 高血压研究 高血压研究
背景情况:
- 原发性阿尔多斯特隆症 (PA) 是高血压的常见原因,显著增加心血管风险和死亡率.
- 精确诊断PA往往是复杂的,因为必须停止药物干扰氨酸- ангиотензин-阿尔多素系统 (RAAS).
- 这对及时有效的患者管理构成了挑战.
研究的目的:
- 为了评估PA的生物化学评估的诊断准确性,而患者仍然服用RAAS干扰药物.
- 为了确定阿尔多与素的比率 (ARR) 是否可以在这些条件下可靠地诊断PA.
- 为在接受治疗的患者中确定PA的可靠诊断标准.
主要方法:
- 分析了一组接受PA查的高血压患者队列.
- 患者根据他们使用RAAS干扰药物和PA的存在来分类.
- 评估了阿尔多与因比率 (ARR) 和其他生化标志物的诊断性能.
主要成果:
- 该研究包括265名患者,其中122人被诊断患有PA,192人接受RAAS干扰治疗.
- 在诊断PA时ARR的ROC曲线下的面积 (AUROC) 在服用RAAS干扰药物的患者中为0.877.
- 一个ARR切线>50显示了76%的灵敏度和81%的特异性.
- 将ARR>50与低血相结合, PA的积极预测值为92.6%.
结论:
- 阿尔多与的比率 (ARR) 是诊断PA的可靠和准确的生物标志物,即使在RAAS干扰治疗期间也是如此.
- 在使用RAAS干扰药物时,ARR>50与低血结合使用可以被认为是PA的标志.
- 这些发现支持在接受相关抗高血压药物的患者中继续使用ARR测试来诊断PA.
相关概念视频
Adrenal Gland Disorders
1.5K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.5K
Myasthenia Gravis: Diagnostic Tests
819
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
819
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Exercise Stress Test
203
Introduction
Exercise stress testing, commonly known as a treadmill test, is a noninvasive procedure used to evaluate cardiovascular function and diagnose heart conditions.
Definition
An exercise stress test measures the heart's response to exertion using a treadmill or stationary bicycle. Chest electrodes record the heart's electrical activity through an ECG, and blood pressure is monitored regularly.
Purposes
Exercise stress testing, commonly known as a treadmill test, is a noninvasive procedure used to evaluate cardiovascular function and diagnose heart conditions.
Definition
An exercise stress test measures the heart's response to exertion using a treadmill or stationary bicycle. Chest electrodes record the heart's electrical activity through an ECG, and blood pressure is monitored regularly.
Purposes
203
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
806
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
806
Antihypertensive Drugs: Direct Renin Inhibitors
616
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
616

